Treatment of Higher-Risk MDS (IPSS-R ≥4.0) Not Immediately Eligible for Allogeneic Transplant
This protocol addresses patients with myelodysplastic syndrome classified as higher-risk (IPSS-R 4.0 or above) who have no major comorbidities but are not immediately eligible for allogeneic stem cell transplantation — due to age over 70 years or the presence of an unfavourable karyotype.
Clinical Scenario
Higher-risk MDS (IPSS-R ≥4.0) with no major comorbidities, where allogeneic SCT is not an immediate option — either because the patient is older than 70 years or carries an unfavourable karyotype. This combination defines a clinically distinct sub-population in which standard transplant-directed pathways do not apply.
Treatment Approach
For patients in this setting, clinical trial enrolment is a key part of the recommended approach — the full structured protocol outlines the decision framework and what is considered when trial participation is not available.
The complete regimen and management algorithm are available via the link below.
References
In patients with higher-risk MDS without major comorbidities who are not immediately eligible for allo-SCT, azacitidine is recommended [I, A].
Other patients
In case of failure or relapse, consider clinical trial or symptomatic treatment.
The recommended approach is to enrol these patients into a clinical trial with investigational agents [IV, B].
DOI: 10.1016/j.annonc.2020.11.002
View source ↗